RxDoctor Payments Data

Kellie Battillo

Family · Palm Coast, FLNPI 1740586288

Payments from drug & device makers

$3,346in general payments, 2019–2025

Across 129 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$833
  • Intuitive Surgical$439
  • Evoke Pharma, Inc.$349
  • Phathom Pharmaceuticals, Inc.$221
  • Johnson & Johnson$174
  • Merck$164
  • plus $1K from 22 others

What the payments were for

  • Speaking & faculty fees$140%
  • Travel & lodging$43913%
  • Food & beverage$2,87386%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,346 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$34,709
Medicare patients
283
Services billed
375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$81,739
LinzessLinaclotide53$45,929
GimotiMetoclopramide Hcl20$41,628
CreonLipase/Protease/Amylase18$36,203
Pantoprazole Sodium350$3,930
Dexlansoprazole DrDexlansoprazole14$3,883
Omeprazole146$2,082
Colestipol Hcl19$1,578
Famotidine122$1,497
Dicyclomine Hcl72$1,284
CholestyramineCholestyramine (With Sugar)16$1,154
Cholestyramine LightCholestyramine13$676
Esomeprazole Magnesium19$588
Ondansetron OdtOndansetron19$478
Lansoprazole15$440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$833$82,13271 claims
Evoke Pharma, Inc.Gimoti$349$41,62820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.

Other family in Palm Coast

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →